| Name | Title | Contact Details |
|---|
Baystate Health is an integrated health care delivery system serving a population of nearly one million people in western Massachusetts. We are one of the largest health systems in New England with more than 12,000 employees, four hospitals, and over 80 medical practices. Baystate Medical Center has the only Level 1 Trauma Center in the region, and the only neonatal and pediatric intensive care units. University of Massachusetts Medical School-Baystate is the only regional campus of the University of Massachusetts Medical School. Baystate Medical Center has been ranked as one of the nation`s top hospitals for 2015-2016 by U.S. News & World Report and for the third time, Baystate Medical Center has been named a Magnet™ hospital for excellence in nursing services.
Refeyn is a company that specializes in label-free single molecule imaging and mass measurement of biomolecules in solution using mass photometry technology.
Upfront`s Care Traffic Control platform proactively reassures and directs patients to the safest and most relevant care options within the health system.
ICTI (Interactive Clinical Technologies) is a Yardley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.